Princess Margaret Hospital

Pizza Nova partners with CHIN Radio to support the Princess Margaret Cancer Foundation this Halloween

Retrieved on: 
Monday, October 23, 2023
Research, Pizza Nova, Education, CHIN, Princess Margaret Hospital, Princess Margaret, Countess of Snowdon, Life, Breast Cancer Awareness Month, CHIN Radio/TV International, Health, The Ride to Conquer Cancer, Cancer, Breast Cancer Research, Breast cancer, Patient, Diagnosis, Nova, Birth control, Pharmaceutical industry

Toronto, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Pizza Nova, Ontario’s family-owned and operated premium pizza brand, will partner with CHIN Radio/TV International, one of Canada’s largest multicultural broadcasters, to support the Princess Margaret Cancer Foundation on Halloween in honour of Breast Cancer Awareness Month.

Key Points: 
  • Toronto, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Pizza Nova, Ontario’s family-owned and operated premium pizza brand, will partner with CHIN Radio/TV International, one of Canada’s largest multicultural broadcasters, to support the Princess Margaret Cancer Foundation on Halloween in honour of Breast Cancer Awareness Month.
  • On October 31, one dollar from every order placed (excluding walk-in orders) with Pizza Nova, at all locations, will be donated to the Princess Margaret Cancer Foundation to support Breast Cancer Research.
  • “Pizza Nova is proud to be partnering with CHIN in support of The Princess Margaret Cancer Foundation during this Breast Cancer Awareness Month,” says Domenic Primucci, president of Pizza Nova.
  • “This incredible collaboration will support life-saving cancer research at The Princess Margaret, one of the top 5 cancer research centres in the world,” said Dr. Miyo Yamashita, President and Chief Executive Officer of The Princess Margaret Cancer Foundation.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Friday, May 26, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

Retrieved on: 
Friday, December 9, 2022
Gene expression, Security (finance), Exact Sciences (company), Prognosis, Recurrence, Swedish, Breast, University of Gothenburg, Diagnosis, Genomic Health, Oncotype (Denmark), Princess, Patient, DNA, Omission, Cancer, Meta-analysis, Annual report, Breast cancer, Exact sciences, Princess Margaret Hospital, Guideline, Risk, News, University, Radiation, Intron, Gene, RNA, Medical imaging

The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.

Key Points: 
  • The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
  • "Exact Sciences' POLAR signature addresses a significant clinical need for those with early-stage, hormone receptor positive breast cancer, identifying which patients may benefit from radiotherapy and which may not," said Rick Baehner, M.D., chief medical officer of Precision Oncology at Exact Sciences.
  • These data are a critical step toward providing patients with a new tool to help ensure better breast cancer treatment decisions."
  • In breast cancer, the Oncotype DX Breast Recurrence Scoretest is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

Pacylex Pharmaceuticals Announces Progress on Early Phase Clinical Trials of PCLX-001 in Patients

Retrieved on: 
Thursday, September 29, 2022
Apoptosis, BC Cancer Agency, Blood, Safety, Trial of the century, Exposition, Research, CHUM, Breast cancer, Breast Cancer Research and Treatment, Society, ASH, American Association, Treatment, Environment, Survival, Patient, Leukemia, NMT, Princess Margaret Hospital, CEO, Protein, Silver, Toxic leukoencephalopathy, Nature Communications, Lung, AML, Association, University, Lymphoma, Cell death, DLBCL, Pharmaceutical industry, Cancer

Edmonton, Alberta--(Newsfile Corp. - September 29, 2022) - Pacylex Pharmaceuticals has dosed 16 patients in the early phase clinical trials of the company's new cancer drug, PCLX-001.

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - September 29, 2022) - Pacylex Pharmaceuticals has dosed 16 patients in the early phase clinical trials of the company's new cancer drug, PCLX-001.
  • In December 2021, Pacylex announced the results of the first patients dosed with PCLX-001 at the American Society of Hematology (ASH) Annual meeting and Exposition.
  • Pacylex has safely completed 4 dose cohorts reaching target drug exposure levels in patients expected to provide benefit in leukemia and lymphoma.
  • Pacylex began clinical studies of the drug in Canada in September 2021 and is currently seeking funds for Phase 2 of clinical trials.

Sarah Downey named President and CEO of CAMH

Retrieved on: 
Wednesday, June 29, 2022
Trustee, CAMH, Patient, Clinical professor, CEO, University Health Network, Research, COVID-19, Goal, Director, Hope, MGH, Policy, American Health, University, Health promotion, Center, Education, Chairperson, Mental health, Centre for Addiction and Mental Health, Health, Lists of diseases, Board, Leadership, Vaccination, Twitter, Physician, Ontario Hospital Association, Addiction, Princess Margaret Hospital, Performance management, Medicine, Management

TORONTO, June 29, 2022 /CNW/ - The Centre for Addiction and Mental Health (CAMH) is pleased to announce the appointment of Sarah Downey as President and Chief Executive Officer (CEO), effective September 6, 2022.

Key Points: 
  • TORONTO, June 29, 2022 /CNW/ - The Centre for Addiction and Mental Health (CAMH) is pleased to announce the appointment of Sarah Downey as President and Chief Executive Officer (CEO), effective September 6, 2022.
  • Sarah is an experienced and visionary health care executive with a passionate commitment to mental health and addictions.
  • She comes to CAMH from Michael Garron Hospital (MGH), where she served as President and CEO for seven years.
  • CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.

Canadian Cancer Society to lead nation in cancer prevention and survivorship work with new innovation hub

Retrieved on: 
Wednesday, November 10, 2021
Family, Canadian Cancer Society, Adoption, Center, Cancer, Leukemia, Lower Mainland, Industry, Abbotsford Regional Hospital and Cancer Centre, MLA, Government, Organization, CEO, Survivor, Disease, CCS, Lawson Health Research Institute, COVID-19, Research, CCPS, Canadian Institutes of Health Research, Policy, University Health Network, Partnership, Human, American Cancer Society, Mental health, Awareness, Solution, Strathcona County, EN, Princess Margaret Hospital, Princess, Environment, Climate change, Patient, Life, Public, Leukemia & Lymphoma Society of Canada, Progress, Dietary supplement, Pharmaceutical industry, Birth control, Medical device

Through the Centre, CCS will augment funding for cancer prevention and survivorship research, bring researchers together, and connect them with the people and organizations that can bring research to life.

Key Points: 
  • Through the Centre, CCS will augment funding for cancer prevention and survivorship research, bring researchers together, and connect them with the people and organizations that can bring research to life.
  • This will give Canadians improved access to new cancer prevention and support programs that improve their physical and mental health.
  • As the voice for Canadians who care about cancer, we work with governments to establish health policies to prevent cancer and better support those living with the disease.
  • No other organization does all that we do to improve lives today and to change the future of cancer forever.

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients

Retrieved on: 
Tuesday, September 14, 2021
Safety, BC Cancer Agency, Patient, Cross Cancer Institute, Princess Margaret Hospital, Pharmaceutical industry

Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .
  • PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
  • Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
  • This open label, dose escalation study will examine the safety and tolerability of PCLX-001.